Table 1.

Comparative treatment efficacy of disease-modifying therapies for relapsing multiple sclerosis

Treatment	Confirmed disability worsening, HR (95% CI) 3 months	Annualized relapse rate, RR (95% CI)
Teriflunomide 14 mg	0.69 (0.53, 0.89)	0.67 (0.58, 0.76)
Interferon beta-1b 250 mcg	0.94 (0.65, 1.32)	0.70 (0.60, 0.80)
Placebo (BSC)	1.00 (1.00, 1.00)	1.00 (1.00, 1.00)

BSC best supportive care, CI confidence interval, HR hazard ratio, RR relative risk